Asset profile
pemvidutide
Peptide
Evidence outlook · lead readout
NCT05989711 · Non-Alcoholic Steatohepatitis (NASH)
The completed lead evidence is positive, with design limits that temper confidence — see the rationale below for exactly which.
NCT05989711: The study randomized 212 participants to two pemvidutide doses or placebo and used quadruple blinding. Its primary endpoints were biopsy-based clinical liver outcomes, but whether those endpoints were met cannot be determined because results are not available.
How the evidence outlook works ↗
Featured trials
Unlock featured-trial analysis
Research includes the instrumental studies, endpoints, key results, design grades, rationales and source links behind the Outlook.
Upcoming events
No upcoming readouts on record for this asset.
All registered studies
Unlock the complete ClinicalTrials.gov registry
Research includes every linked study, indication filters, phase grouping and featured-trial cross-links.
Competitive landscape
Unlock the competitor landscape
Research compares assets by shared mechanism and indication, including each competitor's stage in the relevant market.